QIMR Berghofer Medical Research Institute
19
1
2
15
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 19 trials
100.0%
+13.5% vs industry average
5%
1 trials in Phase 3/4
60%
9 of 15 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (19)
Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum
Role: collaborator
Finding the Optimal Regimen for Mycobacterium Abscessus Treatment
Role: collaborator
Brain and Genetic Predictors of Individual Differences in Pain and Analgesia
Role: collaborator
Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria
Role: collaborator
Experimental Malaria Infection of Healthy Malaria-Naive Adults by Mosquito Bite With the Genetically Modified Plasmodium Falciparum NF54/iGP3 GAP
Role: collaborator
Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy
Role: collaborator
Safety, Tolerability and Antimalarial Activity of Single Doses of OZ439 and PQP
Role: collaborator
Eating Disorders Genetics Initiative
Role: collaborator
Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community
Role: collaborator
Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2
Role: collaborator
Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A
Role: collaborator
Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent
Role: collaborator
Experimental Falciparum Transmission to Anopheles
Role: collaborator
SJ733 Induced Blood Stage Malaria Challenge Study
Role: collaborator
Hookworm Therapy for Coeliac Disease
Role: collaborator
Controlled Human Malaria Infection Model for Evaluation of Transmission-Blocking Interventions - Study 1
Role: collaborator
MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects, Part B
Role: collaborator
A Phase Ib Induced Malaria Infection Study With the Combination of OZ439 and DSM265
Role: collaborator
The Princess Alexandra Hospital and the QIMR Berghofer Medical Research Institute Head and Neck Cancer Study
Role: collaborator
All 19 trials loaded